Intervention: Budesonide

PreclinicalSmall molecule

BBaylor College of Medicine

Intervention: Budesonide is one of 10 small molecule programs targeting Chronic Asthma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic AsthmaActive, not recruiting

Chronic AsthmaPreclinical

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Chronic Asthma

#DrugCompanyPhaseTrials

Effient

CCosette Pharmaceuticals, Inc.

Approved

1 2

Singulair

AstraZeneca

Phase 3

3 3

Flovent

GSK

Phase 3

1 4

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 2

1 5

Comparator: Statins

Merck & Co.

Phase 2

2 6

MK0359

Merck & Co.

Phase 2

1 7

MK0633

Merck & Co.

Phase 2

1 8

Singulair

OOrganon and Co

Preclinical

—9

Laninamivir Octanoate

BBiota Scientific Management Pty Ltd

Phase 1

1 10

Intervention: Budesonide

BBaylor College of Medicine

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Asthma1 trial

Initiation of Chronic Asthma Care Regimens in the Pediatric Emergency Department

Withdrawn·—·N/A·NCT00388739

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Intervention: Budesonide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intervention: Budesonide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intervention: Budesonide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Baylor College of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: BBaylor College of Medicine

Intervention: Budesonide

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Asthma1 trial

References

Drug Info

Quick Facts

Related News